Patient predictors of response to treatment of depression in Alzheimer's disease: the DIADS study

2004 ◽  
Vol 19 (2) ◽  
pp. 144-150 ◽  
Author(s):  
Martin Steinberg ◽  
Cynthia A. Munro ◽  
Quincy Samus ◽  
Peter V.Rabins ◽  
Jason Brandt ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Response To Treatment ◽  
Predictors Of Response ◽  
Treatment Of Depression

RESPONSE TO TREATMENT WITH LEMBOREXANT: SUBJECTS WITH IRREGULAR SLEEP-WAKE RHYTHM DISORDER AND ALZHEIMER’S DISEASE DEMENTIA

2019 ◽  
Vol 15 (7) ◽  
pp. P187 ◽  
Author(s):  
Stephen G. Thein ◽  
Mohammad Bsharat ◽  
Manuel Kemethofer ◽  
Gleb Filippov ◽  
Naoki Kubota ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Response To Treatment ◽  
Rhythm Disorder ◽  
Alzheimer’S Disease Dementia

A Double-Blind, Placebo-Controlled Study of Fluoxetine in Depressed Patients With Alzheimer's Disease

2001 ◽  
Vol 13 (2) ◽  
pp. 233-240 ◽  
Author(s):  
Gustavo M. Petracca ◽  
Eran Chemerinski ◽  
Sergio E. Starkstein
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Rating Scale ◽  
Functional Independence ◽  
Controlled Study ◽  
Consecutive Series ◽  
Hamilton Depression Scale ◽  
Double Blind ◽  
Treatment Of Depression ◽  
Efficacy Measures

Objective: To examine the efficacy of fluoxetine in the treatment of depression in patients with probable Alzheimer's disease (AD). Methods: This double-blind, parallel-design study included a consecutive series of 41 AD subjects meeting DSM-IV criteria for major or minor depression who were randomized to receive fluoxetine (up to 40 mg/day) or identical-appearing placebo. All patients received biweekly evaluations consisting of the Hamilton Depression Scale (HAM-D) and the Clinical Global Impression as primary efficacy measures, and the Mini-Mental State Exam, Hamilton Rating Scale for Anxiety, and the Functional Independence Measure as secondary efficacy measures. Results: Complete remission of depression was found in 47% of subjects treated with fluoxetine and in 33% of subjects treated with placebo. Both the fluoxetine and the placebo groups showed a significant decline in HAM-D scores over time, but the magnitude of mood improvement was similar for both groups. Fluoxetine was well tolerated, and most side effects were mild. Conclusion: Fluoxetine treatment for depression in AD did not differ significantly from treatment with placebo. Our study also confirms the presence of a placebo effect in the treatment of depression in AD.

Paraoxonase 1 Gene Polymorphisms Do Not Influence the Response to Treatment in Alzheimer’s Disease

2011 ◽  
Vol 32 (1) ◽  
pp. 26-31 ◽  
Author(s):  
A. Klimkowicz-Mrowiec ◽  
M. Marona ◽  
K. Spisak ◽  
J. Jagiella ◽  
P. Wolkow ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Gene Polymorphisms ◽  
Paraoxonase 1 ◽  
Response To Treatment

scholarly journals Effects of Aerobic Exercise on Cognition and Activities of Daily Living in Alzheimer’s Disease: A Systematic Review

2021 ◽  
Author(s):  
Vívian Maria Gomes de Oliveira ◽  
Cíntia Gonçalves Nogueira ◽  
Gabriela Ferreira Paticcié ◽  
Leonardo Oliveira Silva ◽  
Igor Jacomedes de Oliveira ◽  
...  
Keyword(s):  
Systematic Review ◽  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Activities Of Daily Living ◽  
Daily Living ◽  
Functional Neuroimaging ◽  
Neuropsychiatric Symptoms ◽  
Well Being ◽  
Response To Treatment ◽  
Alzheimer Dementia

Background: Alzheimer’s disease (AD) represents one of the main causes of cognitive and functional decline in the world. Concomitant with pharmacological treatment, the practice of aerobic exercises (AE) can help in the symptomatic control of the disease. Objectives: To evaluate the effects of AE on activities of daily living and cognition in patients with AD. Methods: A systematic review was undertaken. EMBASE, Pubmed and BVS databases were searched using the terms “Alzheimer disease”, “Alzheimer syndrome” and “Alzheimer dementia”; “aerobic” and “exercise”. The inclusion criteria were: randomized controlled trials from 2016 to 2021, English language studies and human studies. Among 854 studies found, six were included in the review. Results: The potential benefits of AE training in AD patients are: improvement of functioning, quality of life and cognitive performance; better control of neuropsychiatric symptoms and possible reduction of systemic inflammation. Conclusions: AEs are associated with cognitive and functional performance gain in AD, probably related to synaptic plasticity optimization and improvement of the feeling of well-being. Although AEs may improve cognitive and neuropsychiatric symptoms, the response to treatment is individual. Future longitudinal studies with larger cohorts and functional neuroimaging studies are required for a better understanding of the real benefit of AE in AD.

scholarly journals Pharmacological Treatment of Depression in Alzheimer’s Disease: A Challenging Task

2019 ◽  
Vol 10 ◽  
Author(s):  
Tommaso Cassano ◽  
Silvio Calcagnini ◽  
Antonio Carbone ◽  
Vidyasagar Naik Bukke ◽  
Stanislaw Orkisz ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Pharmacological Treatment ◽  
Treatment Of Depression

scholarly journals New drugs in psychiatry: focus on new pharmacological targets

F1000Research ◽  
2017 ◽  
Vol 6 ◽  
pp. 397 ◽  
Author(s):  
Filippo Caraci ◽  
Gian Marco Leggio ◽  
Salvatore Salomone ◽  
Filippo Drago
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cannabinoid Receptors ◽  
Mechanisms Of Action ◽  
New Drugs ◽  
Progressive Decline ◽  
Drug Candidates ◽  
Pharmacological Targets ◽  
Treatment Of Depression ◽  
Dopamine D3

The approval of psychotropic drugs with novel mechanisms of action has been rare in recent years. To address this issue, further analysis of the pathophysiology of neuropsychiatric disorders is essential for identifying new pharmacological targets for psychotropic medications. In this report, we detail drug candidates being examined as treatments for psychiatric disorders. Particular emphasis is placed on agents with novel mechanisms of action that are being tested as therapies for depression, schizophrenia, or Alzheimer’s disease. All of the compounds considered were recently approved for human use or are in advanced clinical trials. Drugs included here are new antipsychotic medications endowed with a preferential affinity at dopamine D3 receptor (cariprazine) or at glutamatergic or cannabinoid receptors, as well as vortioxetine, a drug approved for managing the cognitive deficits associated with major depression. New mechanistic approaches for the treatment of depression include intravenous ketamine or esketamine or intranasal esketamine. As for Alzheimer’s disease, the possible value of passive immunotherapy with agents such as aducanumab is considered to be a potential disease-modifying approach that could slow or halt the progressive decline associated with this devastating disorder.

Visual attention-related processing in Alzheimer's disease

2008 ◽  
Vol 18 (3) ◽  
pp. 229-243 ◽  
Author(s):  
Andrea Tales ◽  
Gillian Porter
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Executive Function ◽  
Visual Perception ◽  
Visual Attention ◽  
Disease Progression ◽  
Neuropsychological Testing ◽  
Response To Treatment ◽  
Disease Markers ◽  
Brain Processing

The clinical diagnosis of Alzheimer's disease (AD) involves neuropsychological testing to assess the integrity of higher order cerebral functions such as memory, cognition, visual perception, language and executive function. However, the onset of AD is insidious and diagnosing the very early stages may be precluded as such tests may lack the necessary sensitivity and specificity. This, together with the potential for similar shortcomings in relation to assessing disease progression and response to treatment, has prompted the search for disease markers based on abnormalities in additional aspects of brain processing. One area receiving increasing investigation is the integrity of visual and visual-attention-related processing.

Sign in / Sign up

Export Citation Format

Share Document